BATON ROUGE, La. – Two abortion-inducing drugs could soon be reclassified as controlled and dangerous substances in Louisiana under a first-of-its-kind bill that received final legislative passage Thursday and is expected to be signed into law by the governor.
Supporters of the reclassification of mifepristone and misoprostol, commonly known as “abortion pills,” say it would protect expectant mothers from coerced abortions, though they cited only one example of that happening, in the state of Texas. Numerous doctors, meanwhile, have said it will make it harder for them to prescribe the medicines, which they also use for other important reproductive health care needs.
Recommended Videos
Passage of the bill comes as both abortion rights advocates and abortion opponents await a final decision from the U.S. Supreme Court on an effort to restrict access to mifepristone. The justices did not appear ready to limit access to the drug on the day they heard arguments.
The GOP-dominated Legislature’s push to reclassify mifepristone and misoprostol could possibly open the door for other Republican states with abortion bans that are seeking tighter restrictions on the drugs. Louisiana currently has a near-total abortion ban in place, applying both to surgical and medical abortions.
Current Louisiana law already requires a prescription for both drugs and makes it a crime to use them to induce an abortion, in most cases. The bill would make it harder to obtain the pills by placing them on the list of Schedule IV drugs under the state’s Uniform Controlled Dangerous Substances Law.
The classification would require doctors to have a specific license to prescribe the drugs, and the drugs would have to be stored in certain facilities that in some cases could end up being located far from rural clinics. Knowingly possessing the drugs without a valid prescription would carry a punishment including hefty fines and jail time. Language in the bill appears to carve out protections for pregnant women who obtain the drug without a prescription for their own consumption.
More than 200 doctors in the state signed a letter to lawmakers warning that the measure could produce a “barrier to physicians’ ease of prescribing appropriate treatment” and cause unnecessary fear and confusion among both patients and doctors. The physicians warn that any delay to obtaining the drugs could lead to worsening outcomes in a state that has one of the highest maternal mortality rates in the country.
“This goes too far. We have not properly vetted this with the health care community and I believe it’s going to lead to further harm down the road,” said Democratic Sen. Royce Duplessis, who voted against the measure. “There’s a reason we rank at the bottom in terms of maternal health outcomes, and this is why.”
The reclassification of the two drugs is contained in an amendment to a bill originating in the Senate that would create the crime of “coerced criminal abortion by means of fraud." Lawmakers in the Senate unanimously supported the original legislation a month ago. Later, bill sponsor Sen. Thomas Pressly pushed for the amendment to reclassify the drugs.
Pressly said both the bill and the amendment were motivated by what happened to his sister Catherine Herring of Texas. In 2022, Herring's husband slipped her seven misoprostol pills in an effort to induce an abortion without her knowledge or consent.
There have been several cases similar to Herring's reported by news outlets over the past 15 years, though none of those cited were in Louisiana.
“The purpose of bringing this legislation is certainly not to prevent these drugs from being used for legitimate health care purposes," Pressly said. "I am simply trying to put safeguards and guardrails in place to keep bad actors from getting these medications.”
The Senate voted 29-7, mainly along party lines, to pass the legislation. In the 39-person Senate there are only five women, all of whom voted in favor of the bill.
In addition to inducing abortions, mifepristone and misoprostol have other common uses, such as treating miscarriages, inducing labor and stopping hemorrhaging.
Mifepristone was approved by the U.S. Food and Drug Administration in 2000 after federal regulators deemed it safe and effective for ending early pregnancies. It’s used in combination with misoprostol, which the FDA has separately approved to treat stomach ulcers.
The drugs are not classified as controlled substances by the federal government because regulators do not view them as carrying a significant risk of misuse. The federal Controlled Substances Act restricts the use and distribution of prescription medications such as opioids, amphetamines, sleeping aids and other drugs that carry the risk of addiction and overdose.
Abortion opponents and conservative Republicans both inside and outside the state have applauded the Louisiana bill. Conversely, the move has been strongly criticized by Democrats, including Vice President Kamala Harris, who in a social media post described it as “absolutely unconscionable.”
The Louisiana legislation now heads to the desk of conservative Republican Gov. Jeff Landry. The governor, who was backed by former President Donald Trump during last year’s gubernatorial election, has indicated his support for the measure, remarking in a recent post on X, “You know you’re doing something right when @KamalaHarris criticizes you.”
Landry’s office did not respond to an emailed request for comment.
A recent survey found that thousands of women in states with abortion bans or restrictions are receiving abortion pills in the mail from states that have laws protecting prescribers. The survey did not specify how many of those cases were in Louisiana.
Louisiana has a near-total abortion ban in place, which applies both to medical and surgical abortions. The only exceptions to the ban are if there is substantial risk of death or impairment to the mother if she continues the pregnancy or in the case of “medically futile” pregnancies, when the fetus has a fatal abnormality.
Currently, 14 states are enforcing bans on abortion at all stages of pregnancy, with limited exceptions.